首页|期刊导航|Cancer Biology & Medicine|Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma

Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma

Gaofeng Zheng Ruyi Xu Heng Mei Xiaoyan Han Donghua He Yanling Weng Cheng Wen Zhuoxiao Cao Zhen Cai

Cancer Biology & Medicine2025，Vol.22Issue(11)：P.1377-1380,4.

Cancer Biology & Medicine2025，Vol.22Issue(11)：P.1377-1380,4.DOI:10.20892/j.issn.2095-3941.2024.0581

Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma

Gaofeng Zheng ¹Ruyi Xu ¹Heng Mei ²Xiaoyan Han ¹Donghua He ¹Yanling Weng ¹Cheng Wen ³Zhuoxiao Cao ³Zhen Cai¹

作者信息

1. Multiple Myeloma Treatment Center and Bone Marrow Transplantation Center,The First Affiliated Hospital,Zhejiang University School of Medicine,Hangzhou 310006,China
2. Institute of Hematology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430022,China
3. Shanghai Simnova Biotechnology Co.,Ltd,Shanghai 200120,China
折叠

摘要

关键词

CAR T/relapsed refractory multiple myeloma/bone marrowmm/phase I clinical study/hemato logical neoplasms/multiple myeloma rrmm become/malignant plasma cells/multiple myeloma mm one

分类

医药卫生

引用本文复制引用

Gaofeng Zheng,Ruyi Xu,Heng Mei,Xiaoyan Han,Donghua He,Yanling Weng,Cheng Wen,Zhuoxiao Cao,Zhen Cai..Phase I clinical study of humanized BCMA-single-domain antibodies targeting CAR-T in patients with relapsed or refractory multiple myeloma[J].Cancer Biology & Medicine,2025,22(11):P.1377-1380,4.

基金项目

supported by grant from the National Natural Science Foundation of China(Grant No.82300231). （Grant No.82300231）

Cancer Biology & Medicine

ISSN：2095-3941

访问量0

下载量0

段落导航